Cargando…
Immunotherapy combinations and chemotherapy sparing schemes in first line non-small cell lung cancer
In recent years, studies have explored different combinations of immunotherapy and chemotherapy. The rationale behind these is the improved survival outcomes of new immunologic therapies used in first-line-treatment of advanced non-small cell lung cancer. Moreover, for the most-studied combinations...
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Baishideng Publishing Group Inc
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8716995/ https://www.ncbi.nlm.nih.gov/pubmed/35070737 http://dx.doi.org/10.5306/wjco.v12.i12.1182 |